Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TNBChemiRNet

Financiado

Cerrado

Enhancing chemotherapy response in triple negative breast cancer TNBC by modul...

Enhancing chemotherapy response in triple negative breast cancer TNBC by modulating miRNA target network and identifying biomarkers of response Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer and therapies are primarily limited to conventional chemotherapy. TNBC patients who respond to neo-adjuvant chemotherapy with a pathological complet... ver más

30/06/2018

BILKENTUNIVERSITY...

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

BILKENT UNIVERSITESI VAKIF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-06-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

BILKENTUNIVERSITY BILIM KENT...

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ChromTrace Tracing epigenetic evolution of triple negative breast cance... 2M€ Cerrado

CNS2023-145055 Cáncer 174K€ Cerrado

SAF2010-20832 CARACTERIZACION GENETICA DE LAS CANCER-STEM-CELLS (CSC) EN T... 36K€ Cerrado

EpiResist Exposing hidden targets of drug resistance in cancer by mapp... 1M€ Cerrado

p38Cure New breast cancer therapies based on available p38 MAPK inhi... 150K€ Cerrado

MIRNATHERAPYNBL New epigenetic therapy for high risk neuroblastoma 100K€ Cerrado

Líder del proyecto

BILKENT UNIVERSITESI VAKIF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer and therapies are primarily limited to conventional chemotherapy. TNBC patients who respond to neo-adjuvant chemotherapy with a pathological complete response (pCR) have excellent 5-year survival (up to 94%). However, this represents the minority of TNBC patients (25-40%). The remaining patients have less than 60% 5-year survival due to aggressive relapse. Therefore, increasing the pCR rate of chemotherapy in TNBC holds great promise for improving survival. Furthermore, it is important to identify biomarkers to predict/stratify TNBC patients with higher probability of response to chemotherapy. Recently, microRNAs (miRNAs), which are 20-22 nucleotide small RNAs, emerged as master regulators of several oncogenic processes including therapy resistance and have great potential to be used as therapeutics due to their ability to repress several oncogenic proteins simultaneously. Moreover, miRNAs have also been shown to be promising biomarkers for diagnosis, prognosis and therapy response in cancer. Herein I propose to study the potential for modulation of miRNAs/their target networks to enhance the response to chemotherapy and to identify biomarker of chemotherapy response in TNBC. In this line, I will develop in vivo chemoresistant models using both xenografts and tumor transplants from an established TNBC mouse model. Combining whole genome miRNA/mRNA sequencing, bioinformatics and network biology, miRNAs/their target network involved in chemoresistance will be identified, and targeted to enhance the chemoresponse of TNBC models. Finally, the biomarker potential of identified miRNAs/targets in TNBC patient tumors will be tested with inter-(national) collaborations from two different countries. Overall, this interdisciplinary study will provide pre-clinical data to enhance chemotherapy response in TNBC and identify biomarkers stratifying patients with higher response rate to chemotherapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores